Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis

Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential role in treating prurigo nodularis...

Related Keywords

San Diego ,California ,United States ,America ,American , ,American Academy Of Dermatology ,Facebook ,Linkedin ,Instagram ,Exchange Commission ,Youtube ,National Organization For Rare Disorders ,Late Breaking Research ,American Academy ,Annual Meeting ,Numerical Rating Scale ,Global Assessment Treatment Success ,North America ,Accessed February ,Markets ,